Conditions: Type 2 Diabetes Mellitus
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 53
Healthy volunteers: no

Brief summary:
The primary purpose of this study is to evaluate the pharmacokinetics (PK) of Dapagliflozin in pediatric subjects with type 2 diabetes mellitus (T2DM)

Detailed description:
Primary purpose: The primary purpose is to assess the pharmacokinetics of a single dose of Dapagliflozin in the range of 2.5 to 10 mg in pediatric subjects aged 10 to 17 years with T2DM

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: Dapagliflozin intervention 2: Dapagliflozin intervention 3: Dapagliflozin
Intervention descriptions: intervention 1: Tablet, Oral, 2.5 mg, Single-dose intervention 2: Tablet, Oral, 5 mg, Single-dose intervention 3: Tablet, Oral, 10 mg, Single-dose

Protocol document: